Bruce Horowitz has been appointed chief operating officer, Provectus. Mr. Horowitz previously served as Provectus’ chief operations consultant since 2017. He has also served as a member of the company’s board. Provectus is a clinical-stage biotechnology company developing a new class of drugs for oncology and dermatology based on a wholly-owned family of chemical small molecules called halogenated xanthenes. Prior to working for Provectus, Mr. Horowitz  served as the managing director of Capi...